UCB's Cimzia(R), The Only PEGylated Anti-TNF, Approved In Europe
Main Category: Arthritis / RheumatologyAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 08 Oct 2009 - 1:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate article
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that the European Commission has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB and was approved in the US in May 2009. Cimzia is one of several products which utilize Enzon's PEGylation technology, including Oncaspar®, Adagen®, PEGINTRON®, Macugen®, and Pegasys®.
"Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon's president and chief executive officer.
Source
Enzon Pharmaceuticals, Inc.
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Arthritis / Rheumatology headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
